Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Colorcon

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Eculizumab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Summary for eculizumab
Tradenames:1
Patents:72
Applicants:1
BLAs:1
Suppliers: see list1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for eculizumab
Pharmacology for eculizumab
Mechanism of ActionComplement Inhibitors

US Patents for eculizumab

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Genelux Corporation (San Diego, CA) 2034-01-02 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (Boston, MA) 2029-11-05 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2033-01-04 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial SHIRE VIROPHARMA INCORPORATED (Lexington, MA) 2039-05-17 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Glycotope GmbH (Berlin, DE) 2026-09-10 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for eculizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0016 France   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
0758904/01 Switzerland   Start Trial FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
C/GB10/015 United Kingdom   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTERED: UK EU/1/07/393/001 20070620
C002/2010 Ireland   Start Trial SPC002/2010: 20100902, EXPIRES: 20200430
00433 Netherlands   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
12/2010 Austria   Start Trial PRODUCT NAME: ECULIZUMAB
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKinsey
Boehringer Ingelheim
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.